Join the BioBridge London Symposium – 18 September 2026

Advancing holistic sexual health through regenerative medicine and autologous biologics

📍 1 Wimpole St, London W1G 0AE

📅 18 September 2026 – 07:30-18:30

As technology sponsor, Regenlab is proud to support this scientific and educational meeting dedicated to advancing knowledge in regenerative medicine and autologous biologics.

Faculty includes

Antonella de Ponte Davi

Obstetrics & Gynaecology, MD

Barcelona, Spain

Dr Wai Gin (Don) Lee

MD, PhD — Uro-Andrology,

London, United Kingdom.

Małgorzata Uchman

Obstetrics & Gynaecology, MD

Warsaw, Poland

Sam Ward

Uro-Andrology, MD

Brussels, Belgium

The scientific meeting will focus on the evolving role of autologous biologics in sexual medicine and intimate health, bringing together experts from andrology and gynaecology to discuss the latest evidence, clinical practice and future directions.

Participants will benefit from a structured educational format designed to strengthen scientific understanding and clinical decision-making.

Key topics include

Clinical applications of autologous biologics

Evidence-based approaches in sexual medicine

Evidence-based approaches in sexual medicine

Future innovations in andrology and gynaecology

Future innovations in andrology and gynaecology

Learn more about the program

Each thematic block is intended to follow a reproducible educational structure: a cover lecture establishing pathology and unmet need; an MD practice contribution; a nurse or advanced-practice perspective where relevant; and a concluding synthesis on evidence, acceptance, governance and the way forward.

Learn more

Call for abstracts now open

Researchers and clinicians are encouraged to share their work and contribute to the scientific discussion. The call for abstracts is now open, with a submission deadline of 24 August 2026.

Abstract submission guidelines

This symposium offers a valuable opportunity to engage with leading experts, explore emerging evidence and participate in discussions on the future of regenerative medicine in sexual health. Registration is now open.

Register now

Disclaimer: Regenlab is the BioBridge Foundation technology sponsor.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

More

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

More

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

More

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

More

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

CM-OA
CM-Skin

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

More

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

More

RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.

More

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

More

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

More

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.

More